LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) announced a quarterly dividend on Tuesday, April 28th. Shareholders of record on Thursday, May 21st will be given a dividend of 0.25 per share by the medical instruments supplier on Thursday, June 4th. This represents a c) dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, May 21st.
LeMaitre Vascular has increased its dividend payment by an average of 0.2%per year over the last three years and has raised its dividend annually for the last 14 consecutive years. LeMaitre Vascular has a payout ratio of 42.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect LeMaitre Vascular to earn $3.27 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 30.6%.
LeMaitre Vascular Trading Up 3.6%
NASDAQ LMAT opened at $100.83 on Tuesday. The stock’s 50-day simple moving average is $109.23 and its two-hundred day simple moving average is $95.02. LeMaitre Vascular has a twelve month low of $78.35 and a twelve month high of $118.01. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of 37.21, a PEG ratio of 2.70 and a beta of 0.60.
Insiders Place Their Bets
In related news, CEO George W. Lemaitre sold 150,000 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the transaction, the chief executive officer owned 1,532,304 shares in the company, valued at $163,588,775.04. The trade was a 8.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David B. Roberts sold 8,464 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the transaction, the director owned 17,979 shares in the company, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 269,891 shares of company stock worth $28,969,086 in the last quarter. 7.40% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Sound Income Strategies LLC increased its holdings in LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 183 shares during the period. Cornerstone Planning Group LLC increased its holdings in LeMaitre Vascular by 534.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 283 shares during the period. Catalyst Capital Advisors LLC purchased a new position in LeMaitre Vascular during the 1st quarter valued at about $32,000. MAI Capital Management purchased a new position in LeMaitre Vascular during the 3rd quarter valued at about $38,000. Finally, Geneos Wealth Management Inc. increased its holdings in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
Featured Stories
- Five stocks we like better than LeMaitre Vascular
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
